We are UK Breast Surgeons who revised together for our exit exams and hope you'll find our revision notes as helpful as we did! We discuss the latest guidelines and landmark evidence behind current practices in breast surgery. This is relevant for anyone revising for FRCS, board exams, fellowship and continuing professional development. Any questions or comments - tweet us @ercstjohn @hirahrizki01 . Thank you to Professor John Benson for helping us to edit this content.
Landmark Trials in Breast Surgery
Claim This Podcastby Edward St John & Hirah Rizki
5 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇬🇧
Podcast Overview
We are UK Breast Surgeons who revised together for our exit exams and hope you'll find our revision notes as helpful as we did! We discuss the latest guidelines and landmark evidence behind current practices in breast surgery. This is relevant for anyone revising for FRCS, board exams, fellowship and continuing professional development. Any questions or comments - tweet us @ercstjohn @hirahrizki01 . Thank you to Professor John Benson for helping us to edit this content.
Language
🇺🇲
Publishing Since
8/20/2020
1 verified contact email on file for Landmark Trials in Breast Surgery
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
September 25, 2020
Bisphosphonates - Landmark trials
Here we discuss the landmark trials for Bisphosphonate treatment in early breast cancer. Below are the links to the papers we discuss: NICE guidance - https://www.nice.org.uk/guidance/ng101 Patterson AH et al. NSABP-B34, 2012 – Lancet Oncology - https://www.ncbi.nlm.nih.gov/pubmed/22704583 EBCTCG 2015 - Lancet - https://www.ncbi.nlm.nih.gov/pubmed/26211824 Cochrane review 2017 - Cochrane Database Syst Rev - https://www.ncbi.nlm.nih.gov/pubmed/29082518 Gralow J.R. et al. SWOG SO307 - J Natl Cancer Inst 2020 - https://pubmed.ncbi.nlm.nih.gov/31693129/ Coleman R et al. AZURE - Lancet Oncology 2014 - https://pubmed.ncbi.nlm.nih.gov/25035292/ Gnant M et al. ABCSG-12 - Lancet Oncology 2011 - https://pubmed.ncbi.nlm.nih.gov/21641868/
September 18, 2020
Axillary Treatment
Here we discuss management of the node positive axilla and cover the indications and evidence behind axillary radiotherapy and de-escalation of axillary surgery. The links to the papers we mention are listed below: ABS Guidelines, 2011 - https://associationofbreastsurgery.org.uk/media/64197/final-axilla-consensus-statement.pdf Donker M et al, EORTC AMAROS, 2014, Lancet oncology - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291166/ Giuliano A et al. ACOSOG Z0011, 2010 – Annals of Surgery - https://www.ncbi.nlm.nih.gov/pubmed/21304082 Giuliano A et al. ACOSOG Z0011 10 year update, USA, 2017 - JAMA - https://www.ncbi.nlm.nih.gov/pubmed/28898379 POSNOC - https://pubmed.ncbi.nlm.nih.gov/26254841 Hansen NM et al., 2009 – Journal of Clinical Oncology - https://pubmed.ncbi.nlm.nih.gov/19720928/ IBCSG 23-01, 2013+ 2018 Lancet Oncology - · 2013, https://www.ncbi.nlm.nih.gov/pubmed/23491275, 2018, https://www.ncbi.nlm.nih.gov/pubmed/30196031
September 18, 2020
Sentinel Lymph Node Biopsy (SLNB)
<p>We discuss the advent of SLNB and the landmark papers. Below are the links to the paper we discuss. </p> <p>Veronesi et al,<strong> </strong>2003 - New England Journal of Medicine<strong>. - https://www.ncbi.nlm.nih.gov/pubmed/12904519</strong></p> <p>Mansel et al, ALMANAC. 2006 - J Natl Cancer Inst. - <a href="https://www.ncbi.nlm.nih.gov/pubmed/16670385"><u><strong>https://www.ncbi.nlm.nih.gov/pubmed/16670385</strong></u></a></p> <p>Krag et al. NSABP-32, 2010 - Lancet Oncology - <u><strong>https://www.ncbi.nlm.nih.gov/pubmed/20863759</strong></u></p> <p>Boreham et al. Cochrane Review, Cochrane Database Systematic Review, 2017 - <a href="https://www.ncbi.nlm.nih.gov/pubmed/28052186"><u><strong>https://www.ncbi.nlm.nih.gov/pubmed/28052186</strong></u></a></p> <p>Goyal et al. ALMANAC sub-analysis, 2006 - Breast Cancer Res Treat. - <a href="https://www.ncbi.nlm.nih.gov/pubmed/16541308"><u><strong>https://www.ncbi.nlm.nih.gov/pubmed/16541308</strong></u></a></p> <p>ASCO Guidelines 2016 - Journal of Clinical Oncology - <a href="https://www.ncbi.nlm.nih.gov/pubmed/27937089"><u><strong>https://www.ncbi.nlm.nih.gov/pubmed/27937089</strong></u></a></p> <p>Green–top Guidelines - <a href="https://associationofbreastsurgery.org.uk/media/64251/z-pregnanty.pdf"><u><strong>https://associationofbreastsurgery.org.uk/media/64251/z-pregnanty.pdf</strong></u></a></p> <p><strong>Huxley</strong> N et al., 2012 - Health Technology Assessment, No. 19.2 - <strong>https://www.ncbi.nlm.nih.gov/books/NBK269043/</strong></p> <p><br></p> <p><br></p> <p><br></p> <p><br></p> <p><br></p> <p><br></p> <p><br></p> <p><br></p>
5 total episodes available
Deep-dive analytics for Landmark Trials in Breast Surgery
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Landmark Trials in Breast Surgery?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.